CA2131550A1 - Therapie genique a l'interferon pour le traitement des troubles vasculaires - Google Patents

Therapie genique a l'interferon pour le traitement des troubles vasculaires

Info

Publication number: CA2131550A1
Authority: CA; Canada
Prior art keywords: ifn; cells; interferon; genes coding; smooth muscle
Prior art date: 1992-02-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002131550A

Other languages

English (en)

Inventor

Andrew Zalewski

Yi Shi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Thomas Jefferson University

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-02-05

Filing date

1993-02-05

Publication date

1993-08-19

1993-02-05 Application filed by Individual filed Critical Individual

1993-08-19 Publication of CA2131550A1 publication Critical patent/CA2131550A1/fr

Status Abandoned legal-status Critical Current

Links

108010050904 Interferons Proteins 0.000 title claims abstract description 69
102000014150 Interferons Human genes 0.000 title claims abstract description 68
229940079322 interferon Drugs 0.000 title claims description 42
238000011282 treatment Methods 0.000 title description 7
238000001415 gene therapy Methods 0.000 title description 3
208000019553 vascular disease Diseases 0.000 title description 3
108090000623 proteins and genes Proteins 0.000 claims abstract description 62
238000000034 method Methods 0.000 claims abstract description 44
210000000329 smooth muscle myocyte Anatomy 0.000 claims abstract description 39
230000004663 cell proliferation Effects 0.000 claims abstract description 9
230000002401 inhibitory effect Effects 0.000 claims abstract description 7
208000027418 Wounds and injury Diseases 0.000 claims description 12
230000006378 damage Effects 0.000 claims description 11
208000014674 injury Diseases 0.000 claims description 11
230000015572 biosynthetic process Effects 0.000 claims description 10
210000004204 blood vessel Anatomy 0.000 claims description 9
239000003937 drug carrier Substances 0.000 claims description 8
239000008194 pharmaceutical composition Substances 0.000 claims description 3
230000001131 transforming effect Effects 0.000 claims description 3
102000008070 Interferon-gamma Human genes 0.000 claims 2
108010074328 Interferon-gamma Proteins 0.000 claims 2
229940044627 gamma-interferon Drugs 0.000 claims 2
239000000203 mixture Substances 0.000 abstract description 9
210000004027 cell Anatomy 0.000 description 67
235000018102 proteins Nutrition 0.000 description 14
102000004169 proteins and genes Human genes 0.000 description 14
238000001890 transfection Methods 0.000 description 13
230000000694 effects Effects 0.000 description 12
230000005764 inhibitory process Effects 0.000 description 11
239000000243 solution Substances 0.000 description 11
239000013598 vector Substances 0.000 description 11
108020004414 DNA Proteins 0.000 description 10
238000001727 in vivo Methods 0.000 description 10
208000037803 restenosis Diseases 0.000 description 10
230000002792 vascular Effects 0.000 description 10
241001465754 Metazoa Species 0.000 description 9
230000012010 growth Effects 0.000 description 9
238000012546 transfer Methods 0.000 description 9
230000014509 gene expression Effects 0.000 description 8
238000012637 gene transfection Methods 0.000 description 8
239000002609 medium Substances 0.000 description 8
230000035755 proliferation Effects 0.000 description 8
108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
208000031481 Pathologic Constriction Diseases 0.000 description 7
210000004351 coronary vessel Anatomy 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
230000001404 mediated effect Effects 0.000 description 7
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
150000001413 amino acids Chemical class 0.000 description 6
210000001367 artery Anatomy 0.000 description 6
239000002502 liposome Substances 0.000 description 6
239000004005 microsphere Substances 0.000 description 6
208000037804 stenosis Diseases 0.000 description 6
230000036262 stenosis Effects 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 5
235000001014 amino acid Nutrition 0.000 description 5
230000001028 anti-proliverative effect Effects 0.000 description 5
230000010261 cell growth Effects 0.000 description 5
238000007887 coronary angioplasty Methods 0.000 description 5
210000001105 femoral artery Anatomy 0.000 description 5
238000011534 incubation Methods 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
230000002035 prolonged effect Effects 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
102000029816 Collagenase Human genes 0.000 description 4
108060005980 Collagenase Proteins 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 4
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
101000817629 Homo sapiens Dymeclin Proteins 0.000 description 4
101150103227 IFN gene Proteins 0.000 description 4
101000972281 Rattus norvegicus Mucin-4 Proteins 0.000 description 4
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
108090000631 Trypsin Proteins 0.000 description 4
102000004142 Trypsin Human genes 0.000 description 4
-1 antibodies Proteins 0.000 description 4
229960002424 collagenase Drugs 0.000 description 4
210000002889 endothelial cell Anatomy 0.000 description 4
239000012091 fetal bovine serum Substances 0.000 description 4
229960002897 heparin Drugs 0.000 description 4
229920000669 heparin Polymers 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
238000011065 in-situ storage Methods 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
230000035515 penetration Effects 0.000 description 4
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
239000012588 trypsin Substances 0.000 description 4
229960001322 trypsin Drugs 0.000 description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
102000008186 Collagen Human genes 0.000 description 3
108010035532 Collagen Proteins 0.000 description 3
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 3
229930040373 Paraformaldehyde Natural products 0.000 description 3
102000035195 Peptidases Human genes 0.000 description 3
108091005804 Peptidases Proteins 0.000 description 3
210000000709 aorta Anatomy 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000010367 cloning Methods 0.000 description 3
229920001436 collagen Polymers 0.000 description 3
230000037213 diet Effects 0.000 description 3
235000005911 diet Nutrition 0.000 description 3
239000003814 drug Substances 0.000 description 3
235000019441 ethanol Nutrition 0.000 description 3
239000000284 extract Substances 0.000 description 3
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
238000007901 in situ hybridization Methods 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
229920002866 paraformaldehyde Polymers 0.000 description 3
230000010412 perfusion Effects 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
238000010186 staining Methods 0.000 description 3
239000000758 substrate Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
108090000317 Chymotrypsin Proteins 0.000 description 2
201000000054 Coronary Restenosis Diseases 0.000 description 2
206010011086 Coronary artery occlusion Diseases 0.000 description 2
206010056489 Coronary artery restenosis Diseases 0.000 description 2
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
102000004889 Interleukin-6 Human genes 0.000 description 2
108090001005 Interleukin-6 Proteins 0.000 description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
239000000006 Nitroglycerin Substances 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
108090000526 Papain Proteins 0.000 description 2
108090000284 Pepsin A Proteins 0.000 description 2
102000057297 Pepsin A Human genes 0.000 description 2
239000004365 Protease Substances 0.000 description 2
230000018199 S phase Effects 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
102100033571 Tissue-type plasminogen activator Human genes 0.000 description 2
108050006955 Tissue-type plasminogen activator Proteins 0.000 description 2
102000009618 Transforming Growth Factors Human genes 0.000 description 2
108010009583 Transforming Growth Factors Proteins 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
230000000702 anti-platelet effect Effects 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
230000010100 anticoagulation Effects 0.000 description 2
230000000923 atherogenic effect Effects 0.000 description 2
238000000376 autoradiography Methods 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
230000022131 cell cycle Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
229960002376 chymotrypsin Drugs 0.000 description 2
238000002586 coronary angiography Methods 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
150000001945 cysteines Chemical class 0.000 description 2
229940009976 deoxycholate Drugs 0.000 description 2
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
239000003599 detergent Substances 0.000 description 2
239000000539 dimer Substances 0.000 description 2
MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 2
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
238000003708 edge detection Methods 0.000 description 2
210000004177 elastic tissue Anatomy 0.000 description 2
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
229960003711 glyceryl trinitrate Drugs 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
229960002591 hydroxyproline Drugs 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
229940047124 interferons Drugs 0.000 description 2
238000011835 investigation Methods 0.000 description 2
QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000003550 marker Substances 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
JFRJCQJVFMHZOO-QZHHGCDDSA-N n-(2-aminoethyl)-2-[4-[[2-[4-[[9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]amino]phenyl]acetyl]amino]phenyl]acetamide Chemical compound C1=CC(CC(=O)NCCN)=CC=C1NC(=O)CC(C=C1)=CC=C1NC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 JFRJCQJVFMHZOO-QZHHGCDDSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
229940055729 papain Drugs 0.000 description 2
235000019834 papain Nutrition 0.000 description 2
229960001412 pentobarbital Drugs 0.000 description 2
229940111202 pepsin Drugs 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
239000000523 sample Substances 0.000 description 2
239000012679 serum free medium Substances 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
239000007921 spray Substances 0.000 description 2
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
102000003390 tumor necrosis factor Human genes 0.000 description 2
229960005356 urokinase Drugs 0.000 description 2
238000001262 western blot Methods 0.000 description 2
101150110188 30 gene Proteins 0.000 description 1
UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
206010003225 Arteriospasm coronary Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
101800001288 Atrial natriuretic factor Proteins 0.000 description 1
101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
208000007204 Brain death Diseases 0.000 description 1
102000005600 Cathepsins Human genes 0.000 description 1
108010084457 Cathepsins Proteins 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
102100022641 Coagulation factor IX Human genes 0.000 description 1
208000001778 Coronary Occlusion Diseases 0.000 description 1
208000003890 Coronary Vasospasm Diseases 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
241000701867 Enterobacteria phage T7 Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108010076282 Factor IX Proteins 0.000 description 1
102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
230000035519 G0 Phase Effects 0.000 description 1
230000010337 G2 phase Effects 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000004547 Glucosylceramidase Human genes 0.000 description 1
108010017544 Glucosylceramidase Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
102000007625 Hirudins Human genes 0.000 description 1
108010007267 Hirudins Proteins 0.000 description 1
101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
101000976075 Homo sapiens Insulin Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102100039064 Interleukin-3 Human genes 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
241001529936 Murinae Species 0.000 description 1
102000003505 Myosin Human genes 0.000 description 1
108060008487 Myosin Proteins 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
108010081690 Pertussis Toxin Proteins 0.000 description 1
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
108010059712 Pronase Proteins 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
108091008109 Pseudogenes Proteins 0.000 description 1
102000057361 Pseudogenes Human genes 0.000 description 1
101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
108700008625 Reporter Genes Proteins 0.000 description 1
206010038997 Retroviral infections Diseases 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
241000282887 Suidae Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
241000700605 Viruses Species 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
229960005054 acepromazine Drugs 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
208000037919 acquired disease Diseases 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229940048479 ampicillin 250 mg Drugs 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
238000002583 angiography Methods 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000001621 anti-mitogenic effect Effects 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000027455 binding Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
210000001736 capillary Anatomy 0.000 description 1
150000001720 carbohydrates Chemical group 0.000 description 1
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
108091092328 cellular RNA Proteins 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
230000014107 chromosome localization Effects 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000001816 cooling Methods 0.000 description 1
201000011634 coronary artery vasospasm Diseases 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
OGGXGZAMXPVRFZ-UHFFFAOYSA-M dimethylarsinate Chemical compound C[As](C)([O-])=O OGGXGZAMXPVRFZ-UHFFFAOYSA-M 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
108010007093 dispase Proteins 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000012636 effector Substances 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
229960004222 factor ix Drugs 0.000 description 1
210000003195 fascia Anatomy 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
230000010247 heart contraction Effects 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
230000002439 hemostatic effect Effects 0.000 description 1
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
229940006607 hirudin Drugs 0.000 description 1
210000003917 human chromosome Anatomy 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
210000003090 iliac artery Anatomy 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940100601 interleukin-6 Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
230000008069 intimal proliferation Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229960004184 ketamine hydrochloride Drugs 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000012120 mounting media Substances 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
239000013641 positive control Substances 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000010837 receptor-mediated endocytosis Effects 0.000 description 1
108010043277 recombinant soluble CD4 Proteins 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
230000000250 revascularization Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000017550 sodium carbonate Nutrition 0.000 description 1
NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
229960005202 streptokinase Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002889 sympathetic effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
239000012859 tissue stain Substances 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
238000002627 tracheal intubation Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
210000004231 tunica media Anatomy 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
208000003663 ventricular fibrillation Diseases 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1
108010047303 von Willebrand Factor Proteins 0.000 description 1
102100036537 von Willebrand factor Human genes 0.000 description 1
229960001134 von willebrand factor Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000008096 xylene Substances 0.000 description 1
101150069452 z gene Proteins 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA002131550A 1992-02-05 1993-02-05 Therapie genique a l'interferon pour le traitement des troubles vasculaires Abandoned CA2131550A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US83145392A	1992-02-05	1992-02-05
US831,453		1992-02-05
PCT/US1993/001072 WO1993015609A1 (fr)	1992-02-05	1993-02-05	Therapie genique par interferons pour le traitement des pathologies vasculaires

Publications (1)

Publication Number	Publication Date
CA2131550A1 true CA2131550A1 (fr)	1993-08-19

Family

ID=25259093

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002131550A Abandoned CA2131550A1 (fr)	1992-02-05	1993-02-05	Therapie genique a l'interferon pour le traitement des troubles vasculaires

Country Status (3)

Country	Link
EP (1)	EP0671954A1 (fr)
CA (1)	CA2131550A1 (fr)
WO (1)	WO1993015609A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5545723A (en) *	1994-03-15	1996-08-13	Biogen Inc.	Muteins of IFN-β
WO1995025547A1 (fr) *	1994-03-24	1995-09-28	University Of Washington	Dispositif et methodes d'implantation de cellules ayant subi une transduction
EP0904373A1 (fr)	1996-03-14	1999-03-31	The Immune Response Corporation	Apport cible de genes codant l'interferon
US6140305A (en)	1996-04-04	2000-10-31	Bio-Rad Laboratories, Inc.	Hereditary hemochromatosis gene products
US7026116B1 (en)	1996-04-04	2006-04-11	Bio-Rad Laboratories, Inc.	Polymorphisms in the region of the human hemochromatosis gene
US6849399B1 (en)	1996-05-23	2005-02-01	Bio-Rad Laboratories, Inc.	Methods and compositions for diagnosis and treatment of iron misregulation diseases
EP2356998A1 (fr)	2010-02-17	2011-08-17	Université de Liège	Composition pharmaceutique pour le traitement de maladies liées à la thrombose comprenant un fragment de protéine de la famille des lactogènes placentaires de l'hormone de croissance de type prolactine
DK2536747T3 (en)	2010-02-19	2017-12-04	Université de Liège	POLYNUCLEOTIDE USED FOR THE TREATMENT OF INFLUENZA A VIRUS-INDUCED DISEASES AND CODING MODIFIED MX PROTEIN, THE MODIFIED MODIFIED MX PROTEIN, AND A TRANSGENT ANIMATED DRIVE, AS AN EXTENDED ANIMALS, AS AN EXTERNAL DRIVE, AS AN EXTENDED ANIMALS
WO2012013249A1 (fr)	2010-07-30	2012-02-02	Université de Liège	Protéine 1 de la matrice dentinaire (dmp1) pour l'utilisation dans des compositions pharmaceutiques

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3273597D1 (en) *	1981-11-28	1986-11-06	Sunstar Kk	Pharmaceutical composition containing interferon in stable state
SE462364B (sv) *	1988-09-30	1990-06-18	Goeran Hansson	Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos
WO1990011734A1 (fr) *	1989-03-31	1990-10-18	The Regents Of The University Of Michigan	Traitement de maladies par instillation specifique au site de cellules ou transformation specifique au site de cellules, et kits utilises dans ce traitement

1993
- 1993-02-05 CA CA002131550A patent/CA2131550A1/fr not_active Abandoned
- 1993-02-05 WO PCT/US1993/001072 patent/WO1993015609A1/fr not_active Ceased
- 1993-02-05 EP EP93904949A patent/EP0671954A1/fr not_active Withdrawn

Also Published As

Publication number	Publication date
EP0671954A1 (fr)	1995-09-20
WO1993015609A1 (fr)	1993-08-19
EP0671954A4 (fr)	1995-10-11

Publication	Publication Date	Title
US5707969A (en)	1998-01-13	Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5652225A (en)	1997-07-29	Methods and products for nucleic acid delivery
Guzman et al.	1993	Efficient and selective adenovirus-mediated gene transfer into vascular neointima.
US6482406B1 (en)	2002-11-19	Cell-based gene therapy for the pulmonary system
Tabata et al.	1997	Arterial gene transfer of acidic fibroblast growth factor for therapeutic angiogenesis in vivo: critical role of secretion signal in use of naked DNA
US7285540B2 (en)	2007-10-23	Medicament comprising HGF gene
EP1213032A1 (fr)	2002-06-12	Traitement de pathologies par instillation sitospécifique de cellules ou par transformation sitospécifique de cellules et trousses prévues à cet effet
US20160250290A1 (en)	2016-09-01	Gene therapy for diabetic ischemic disease
HU223957B1 (hu)	2005-03-29	A VEGF fehérje vagy egy ezt kódoló nukleinsav terápiás alkalmazása és implantátum, különösen érbelhártya hiperplázia esetében
CA2131550A1 (fr)	1993-08-19	Therapie genique a l'interferon pour le traitement des troubles vasculaires
WO1993000052A1 (fr)	1993-01-07	Traitement de pathologies par instillation sitospecifique de cellules ou par transformation sitospecifique de cellules et trousses prevues a cet effet
JPWO2001032220A1 (ja)	2003-05-20	糖尿病性虚血性疾患遺伝子治療
WO1990011734A1 (fr)	1990-10-18	Traitement de maladies par instillation specifique au site de cellules ou transformation specifique au site de cellules, et kits utilises dans ce traitement
Ibukiyama	1996	Angiogenesis Angiogenic Therapy Using Fibroblast Growth Factors and Vascular Endothelial Growth Factors for Ischemic Vascular Lesions
JP3380573B2 (ja)	2003-02-24	Ｔｃｆ−ｉｉを有効成分とする蛋白合成促進剤
US7238673B2 (en)	2007-07-03	Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP0753312A1 (fr)	1997-01-15	Medicament contre l'arteriosclerose
KR20010102932A (ko)	2001-11-17	안지오포이에틴-1을 포함하는 제약 조성물 및 그의 용도
EP1220679B1 (fr)	2007-06-13	Therapie genique cellulaire pour le systeme pulmonaire
Shively et al.	1996	Research initiatives in vascular disease
US20020034503A1 (en)	2002-03-21	Retrovirus-mediated gene transfer

Legal Events

Date	Code	Title	Description
1996-08-05	FZDE	Discontinued